US2015366893A1PendingUtilityA1
Substituted purine and 7-deazapurine compounds
Est. expiryDec 3, 2030(~4.4 yrs left)· nominal 20-yr term from priority
Inventors:Edward J. OlhavaRichard ChesworthKevin Wayne KuntzVictoria M. RichonRoy M. PollockScott R. Daigle
A61P 35/02A61P 43/00A61P 35/00A61P 9/00A61P 29/00A61P 25/28A61P 3/00A61K 31/52C07H 19/14C07H 19/16A61K 31/519A61K 31/7076C07H 19/167C07D 473/34A61K 31/7064C07D 487/04C07H 19/04A61P 25/00
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a DOT1L inhibitor.
3 . A method of treating hematological cancer comprising administering to a subject in need thereof a therapeutically effective amount of a DOT1L inhibitor.
4 . A method of treating leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a DOT1L inhibitor.
5 . The method of claim 4 , wherein the leukemia is acute myeloid leukemia, acute lymphocytic leukemia or mixed lineage leukemia.
6 . The method of claim 4 , wherein the leukemia is a MLL-rearranged leukemia.
7 . The method of claim 4 , wherein the leukemia is a leukemia characterized by a partial tandem duplication of the MLL gene (MLL-PTD).Join the waitlist — get patent alerts
Track US2015366893A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.